GEN Exclusives

More »

GEN News Highlights

More »
Dec 23, 2010

AstraZeneca and Abbott Pull NDA for Lipidemia Drug

  • AstraZeneca and Abbott are ceasing development of the FDA-filed mixed lipidemia therapy candidate Certriad™. The drug is a combination of AstraZeneca’s Crestor (rosuvastatin calcium) and Abbott’s Trilipix (fenofibric acid).

    The firms had filed an NDA with FDA for Certriad in June 2009. In March received a complete response letter (CRL) from the agency.

    They say the joint decision to drop the drug follows a careful review of the CRL and the resulting regulatory delay, which led them to conclude that development of Certriad is no longer commercially viable.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Alzheimer's Therapies

Do you think an effective treatment for Alzheimer’s will be found within the next 10–15 years?